Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor

Gang Du1, Linlin Zhao1,2, Yumei Zheng1,3

  • 1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Cell Research
|January 5, 2023
PubMed

Insights

Death receptor 5 (DR5) forms autoinhibitory preclusters on cell surfaces. Disrupting these preclusters with single-domain antibodies (sdAbs) activates DR5 signaling, offering new therapeutic strategies for cancer and immune disorders.

Area of Science:

  • Structural biology
  • Immunology
  • Cancer biology

Background:

  • Members of the tumor necrosis factor receptor superfamily (TNFRSF) are crucial therapeutic targets for cancer and immune cell modulation.
  • The preligand association states of TNFRSF, essential for disease interference, have lacked structural characterization.

Purpose of the Study:

  • To structurally characterize the self-association of the death receptor 5 ectodomain (DR5-ECD).
  • To elucidate the role of DR5 preligand association in receptor signaling and its potential as a therapeutic target.

Main Methods:

  • Nuclear magnetic resonance (NMR) spectroscopy to determine the self-association structure of DR5-ECD.
  • Structure-guided mutagenesis to validate the preligand association structure on cells.
  • Functional assays using single-domain antibodies (sdAbs) to assess receptor activation.

Main Results:

  • DR5-ECD forms specific self-associated structures on lipid bilayers with two distinct interaction interfaces.
  • This preligand association structure is present on DR5-expressing cells and functions in an autoinhibitory manner.
  • Monovalent agonistic sdAbs that partially dissociate DR5 preclusters sensitize the receptor to TRAIL and induce signaling independently of TRAIL.

Conclusions:

  • DR5 receptors form structurally defined, signaling-incompetent preclusters.
  • Agonistic molecules can activate TNFRSF by disrupting preclusters and promoting signaling-productive clusters.
  • Targeting receptor preligand clustering presents a novel strategy for developing TNFRSF-based therapeutics.

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.1K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.2K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.4K
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
7.4K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.6K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.5K